Nifuroxazide suppresses PD-L1 expression and enhances the efficacy of radiotherapy in hepatocellular carcinoma

被引:5
|
作者
Zhao, Tiesuo [1 ,2 ,3 ]
Wei, Pengkun [1 ,2 ,4 ]
Zhang, Congli [1 ,2 ]
Zhou, Shijie [1 ,2 ]
Liang, Lirui [1 ,2 ]
Guo, Shuoshuo [1 ,2 ]
Yin, Zhinan [5 ]
Cheng, Sichang [1 ,2 ]
Gan, Zerui [1 ,2 ]
Xia, Yuanling [1 ,2 ]
Zhang, Yongxi [6 ]
Guo, Sheng [1 ,2 ]
Zhong, Jiateng [2 ]
Yang, Zishan [1 ,2 ]
Tu, Fei [2 ]
Wang, Qianqing [7 ,8 ]
Bai, Jin [7 ,8 ]
Ren, Feng [3 ]
Feng, Zhiwei [1 ,2 ]
Jia, Huijie [2 ]
机构
[1] Xinxiang Med Univ, Sch Basic Med Sci, Dept Immunol, Xinxiang, Peoples R China
[2] Xinxiang Med Univ, Xinxiang Engn Technol Res Ctr Immune Checkpoint Dr, Xinxiang, Peoples R China
[3] Xinxiang Med Univ, Henan Int Joint Lab Immun & Targeted Therapy Liver, Xinxiang, Peoples R China
[4] Zhengzhou Univ, Zhengzhou Cent Hosp, Zhengzhou, Peoples R China
[5] Jinan Univ, Biomed Translat Res Inst, Fac Med Sci, Guangzhou, Peoples R China
[6] Xinxiang Med Univ, Affiliated Hosp 3, Dept Oncol, Xinxiang, Peoples R China
[7] Xinxiang Cent Hosp, Dept Gynecol, Xinxiang, Peoples R China
[8] Xinxiang Med Univ, Clin Coll 4, Xinxiang, Peoples R China
来源
ELIFE | 2024年 / 12卷
关键词
hepatocellular carcinoma; PD-L1; radiotherapy; cancer immunotherapy; Mouse;
D O I
10.7554/eLife.90911
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Radiation therapy is a primary treatment for hepatocellular carcinoma (HCC), but its effectiveness can be diminished by various factors. The over-expression of PD-L1 has been identified as a critical reason for radiotherapy resistance. Previous studies have demonstrated that nifuroxazide exerts antitumor activity by damaging the Stat3 pathway, but its efficacy against PD-L1 has remained unclear. In this study, we investigated whether nifuroxazide could enhance the efficacy of radiotherapy in HCC by reducing PD-L1 expression. Our results showed that nifuroxazide significantly increased the sensitivity of tumor cells to radiation therapy by inhibiting cell proliferation and migration while increasing apoptosis in vitro. Additionally, nifuroxazide attenuated the up-regulation of PD-L1 expression induced by irradiation, which may be associated with increased degradation of PD-L1 through the ubiquitination-proteasome pathway. Furthermore, nifuroxazide greatly enhanced the efficacy of radiation therapy in H22-bearing mice by inhibiting tumor growth, improving survival, boosting the activation of T lymphocytes, and decelerating the ratios of Treg cells in spleens. Importantly, nifuroxazide limited the increased expression of PD-L1 in tumor tissues induced by radiation therapy. This study confirms, for the first time, that nifuroxazide can augment PD-L1 degradation to improve the efficacy of radiation therapy in HCC-bearing mice.
引用
收藏
页数:22
相关论文
共 50 条
  • [31] Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma
    Gong, Xue-Qin
    Liu, Ning
    Tao, Yun-Yun
    Li, Li
    Li, Zu-Mao
    Yang, Lin
    Zhang, Xiao-Ming
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [32] Characterizing PD-L1/PD-1 expression in hepatocellular carcinoma and implications on postresection treatment response.
    Farha, Mark
    Green, Michael
    El Naga, Issam
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma
    Xue-Qin Gong
    Ning Liu
    Yun-Yun Tao
    Li Li
    Zu-Mao Li
    Lin Yang
    Xiao-Ming Zhang
    Scientific Reports, 13
  • [34] M1-like macrophages induce PD-L1 expression in hepatocellular carcinoma cells
    Zong, Z.
    Zou, J.
    Mao, R.
    Ma, C.
    Li, N.
    Shi, Y.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 105 - 105
  • [35] Synergistic effect of IFN-γ and IL-1β on PD-L1 expression in hepatocellular carcinoma
    Numata, Yasunao
    Akutsu, Noriyuki
    Ishigami, Keisuke
    Koide, Hideyuki
    Wagatsuma, Kohei
    Motoya, Masayo
    Sasaki, Shigeru
    Nakase, Hiroshi
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2022, 30
  • [36] ABCB5 knockdown suppresses tumor-intrinsic expression of immune checkpoint regulators PD-1 and PD-L1 in hepatocellular carcinoma (HCC)
    Yeung, Chun Philip
    Wilson, Brian J.
    Sasamoto, Yuzuru
    Waaga-Gasser, Ana Maria
    Karpova, Svetlana
    Guo, Qin
    Frank, Natasha Y.
    Frank, Markus H.
    CANCER RESEARCH, 2023, 83 (07)
  • [37] Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression
    Yang, Xiaobo
    Shi, Junping
    Chen, Xiaoqian
    Jiang, Yan
    Zhao, Haitao
    ONCOLOGIST, 2020, 25 (06): : 470 - 474
  • [38] PD-L1 and LAG3 Expression in Hepatocellular Carcinoma Associated with HCV and Steatohepatitis
    Xing, Dongmei
    Luan, Lan
    Zhu, Qingfeng
    Gani, Faiz
    Pawlik, Timothy
    Taube, Janis M.
    Anders, Robert A.
    LABORATORY INVESTIGATION, 2017, 97 : 426A - 426A
  • [39] Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma
    Deng, Haijing
    Kan, Anna
    Lyu, Ning
    He, Meng
    Huang, Xin
    Qiao, Shuang
    Li, Shaolong
    Lu, Wenhua
    Xie, Qiankun
    Chen, Huiming
    Lai, Jinfa
    Chen, Qifeng
    Jiang, Xiongying
    Liu, Shousheng
    Zhang, Zhenfeng
    Zhao, Ming
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (06)
  • [40] Tumor-stroma ratio predicts prognosis and PD-L1 expression in hepatocellular carcinoma
    Wang, Dong
    Luo, Jia
    Tao, YiMing
    BMC CANCER, 2023, 23 (01)